Identification of lung cancer with high sensitivity and specificity by blood testing.
Identification of lung cancer with high sensitivity and specificity by blood testing.
复制标题
DOI：
10.1186/1465-9921-11-18
复制
发表时间：
2010-02-10
影响因子：
5.8
通讯作者：
Meese E
中科院分区：
文献类型：
--
作者：
Leidinger P;Keller A;Heisel S;Ludwig N;Rheinheimer S;Klein V;Andres C;Staratschek-Jox A;Wolf J;Stoelben E;Stephan B;Stehle I;Hamacher J;Huwer H;Lenhof HP;Meese E
肺癌是一种非常常见和致命的肿瘤，具有可识别的风险人群。细胞学分析和胸部X线检查未能降低死亡率，CT筛查仍有争议。最近的研究首次提供了自身抗原作为肺癌标志物的潜在用途的证据。我们使用了扩展的阵列抗原面板，并通过新开发的计算机辅助图像分析程序确定了来自不同类型肺癌、不同常见非肿瘤肺部病变和无任何肺部疾病的对照患者血清的自身抗体特征。使用线性核支持向量机和10重交叉验证对所得签名进行分类。这种新方法可以区分肺癌患者和无任何肺部疾病的对照组，特异性为97.0%，灵敏度为97.9%，准确度为97.6%。IA/IB期肿瘤和对照的分类产生了97.6%的特异性，75.9%的敏感性和92.9%的准确性。肺癌患者与非肿瘤肺部病变患者的鉴别准确率达到88.5%。我们能够以高准确度将肺癌患者与无任何肺部疾病的受试者分开。此外，肺癌患者可以与其他非肿瘤性肺部疾病患者区分开来。这些结果提供了明确的证据，表明血液检测为肺癌的早期诊断开辟了新的途径。
Lung cancer is a very frequent and lethal tumor with an identifiable risk population. Cytological analysis and chest X-ray failed to reduce mortality, and CT screenings are still controversially discussed. Recent studies provided first evidence for the potential usefulness of autoantigens as markers for lung cancer. We used extended panels of arrayed antigens and determined autoantibody signatures of sera from patients with different kinds of lung cancer, different common non-tumor lung pathologies, and controls without any lung disease by a newly developed computer aided image analysis procedure. The resulting signatures were classified using linear kernel Support Vector Machines and 10-fold cross-validation. The novel approach allowed for discriminating lung cancer patients from controls without any lung disease with a specificity of 97.0%, a sensitivity of 97.9%, and an accuracy of 97.6%. The classification of stage IA/IB tumors and controls yielded a specificity of 97.6%, a sensitivity of 75.9%, and an accuracy of 92.9%. The discrimination of lung cancer patients from patients with non-tumor lung pathologies reached an accuracy of 88.5%. We were able to separate lung cancer patients from subjects without any lung disease with high accuracy. Furthermore, lung cancer patients could be seprated from patients with other non-tumor lung diseases. These results provide clear evidence that blood-based tests open new avenues for the early diagnosis of lung cancer.
登录
查看更多内容
DOI：
10.1073/pnas.171320598
发表时间：
2001-08-14
影响因子：
11.1
作者：
Brichory, FM;Misek, DE;Hanash, SM
通讯作者：
Hanash, SM
影响因子：
5.8
作者：
Henschke, Claudia I.;Yankelevitz, David F.
通讯作者：
Yankelevitz, David F.
DOI：
10.1073/pnas.0710735105
发表时间：
2008-01-08
影响因子：
11.1
作者：
Rauch, Tibor A.;Zhong, Xueyan;Pfeifer, Gerd P.
通讯作者：
Pfeifer, Gerd P.
影响因子：
6.4
作者：
Leidinger，Petra;Keller，Andreas;Meese，Eckart
通讯作者：
Meese，Eckart
影响因子：
5.8
作者：
Leidinger, Petra;Keller, Andreas;Meese, Eckart
通讯作者：
Meese, Eckart